RANI - Rani Therapeutics says CEO Imran buys 20K class A shares
2023-12-01 10:20:04 ET
More on Rani Therapeutics
- Rani Therapeutics: Excellent Technology But Major Risks Ahead
- Rani Therapeutics GAAP EPS of -$0.36 misses by $0.05
- Canaccord believes Rani restructuring will help speed development
For further details see:
Rani Therapeutics says CEO Imran buys 20K class A shares